IL-2 Immunotherapy Fails To Benefit HIV-infected Individuals Already Taking Antiretrovirals
Friday, February 20, 2009 - 23:28
in Health & Medicine
Providing a synthetic form of the immune system protein interleukin-2 to HIV-infected individuals already taking combination antiretroviral therapy boosts their numbers of CD4+ T cells, the key white blood cells destroyed by HIV, but fails to reduce their risk of HIV-associated opportunistic diseases or death compared with combination antiretroviral therapy alone.